Bright Minds Biosciences (DRUG) News Today $28.16 +0.29 (+1.02%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period 40,379 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by Millennium Management LLCMillennium Management LLC acquired a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 40,379 shares of the company's stock, valued at approximately $1,454,000June 4, 2025 | marketbeat.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from BrokeragesJune 1, 2025 | americanbankingnews.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from AnalystsShares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and two have giJune 1, 2025 | marketbeat.comBright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | finance.yahoo.comWhat is Chardan Capital's Forecast for DRUG FY2025 Earnings?Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Chardan Capital upped their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued on Wednesday, May 21st. Chardan Capital analyst R. Li now forecasts that the company will post earnings of ($1.23) per share fMay 27, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for DRUG EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Analysts at HC Wainwright cut their Q3 2025 earnings per share estimates for Bright Minds Biosciences in a research note issued on Thursday, May 22nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings perMay 27, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street ZenWall Street Zen downgraded shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research report on Thursday.May 24, 2025 | marketbeat.comChardan Capital Reiterates Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG)Chardan Capital reissued a "buy" rating and set a $80.00 price target on shares of Bright Minds Biosciences in a research report on Wednesday.May 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 135,189 Bright Minds Biosciences Inc. (NASDAQ:DRUG)Point72 Asset Management L.P. bought a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 135,189 shares of the company's stMay 22, 2025 | marketbeat.comBright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025May 20, 2025 | globenewswire.comJanus Henderson Group PLC Buys New Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Janus Henderson Group PLC bought a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 508,776 shares of the company's stock, valued at approximately $18,392,000. Janus Henderson Group PLC oMay 18, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Upgraded to Strong-Buy at Cantor FitzgeraldCantor Fitzgerald upgraded shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Tuesday.May 17, 2025 | marketbeat.comBright Minds Biosciences (DRUG) to Release Earnings on WednesdayBright Minds Biosciences (NASDAQ:DRUG) will be releasing earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-bright-minds-biosciences-inc-stock/)May 16, 2025 | marketbeat.comTD Cowen Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)TD Cowen initiated coverage on shares of Bright Minds Biosciences in a research report on Tuesday. They issued a "buy" rating on the stock.May 15, 2025 | marketbeat.comTD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationMay 14, 2025 | msn.comBright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101May 14, 2025 | finance.yahoo.comChardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG)May 9, 2025 | theglobeandmail.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from BrokeragesBright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommenMay 9, 2025 | marketbeat.comChardan Capital Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)Chardan Capital assumed coverage on shares of Bright Minds Biosciences in a research report on Wednesday. They set a "buy" rating and a $80.00 price target on the stock.May 9, 2025 | marketbeat.comEpilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock UpsideMay 7, 2025 | benzinga.comChardan Capital Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationMay 7, 2025 | msn.comSchonfeld Strategic Advisors LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Schonfeld Strategic Advisors LLC purchased a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 69,812 shaMay 7, 2025 | marketbeat.comAcuta Capital Partners LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Acuta Capital Partners LLC acquired a new position in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 69,124 shares of the company's stock, valued atMay 4, 2025 | marketbeat.com460,829 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by RA Capital Management L.P.RA Capital Management L.P. acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 460,829 shares of the compaMay 3, 2025 | marketbeat.comAdvisorShares Investments LLC Sells 179,345 Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG)AdvisorShares Investments LLC decreased its position in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) by 98.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,075 shares of the company's stockMay 2, 2025 | marketbeat.com44,580 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by Boothbay Fund Management LLCBoothbay Fund Management LLC acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 44,580 shares of the company's stock, valued at approximately $1,606,000. Boothbay FuMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Acquires New Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Adage Capital Partners GP L.L.C. bought a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 132,500 shares of the company's stock, valued at approximateMay 1, 2025 | marketbeat.comBright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 StudyApril 28, 2025 | globenewswire.comVivo Capital LLC Invests $9.06 Million in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Vivo Capital LLC acquired a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 251,572 shares of the company's stock, valued at approximately $9,06April 23, 2025 | marketbeat.comWalleye Capital LLC Acquires New Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Walleye Capital LLC bought a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 103,192 shares of the company's stock,April 20, 2025 | marketbeat.comBright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025April 17, 2025 | seekingalpha.comBright Minds Biosciences Inc. Common Stock (DRUG) After-HoursApril 14, 2025 | nasdaq.comSpringhill Fund Asset Management HK Co Ltd Purchases Shares of 60,648 Bright Minds Biosciences Inc. (NASDAQ:DRUG)Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 60,648 shares of the company'April 8, 2025 | marketbeat.comAtika Capital Management LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)Atika Capital Management LLC bought a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 15,000 shares of the company's stock, valued atApril 8, 2025 | marketbeat.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Short Interest UpdateBright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 107,700 shares, a decline of 14.8% from the February 13th total of 126,400 shares. Approximately 2.2% of the company's stock are sold short. Based on an average trading volume of 79,700 shares, the days-to-cover ratio is currently 1.4 days.March 20, 2025 | marketbeat.comCantor Fitzgerald Has Weak Forecast for DRUG FY2025 EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued to clients and investors on Thursday, March 13th. Cantor Fitzgerald analyst C. Duncan now expects tMarch 17, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% - Here's WhyBright Minds Biosciences (NASDAQ:DRUG) Shares Down 0.8% - Here's What HappenedMarch 15, 2025 | marketbeat.comBright Minds Biosciences expands Scientific Advisory BoardMarch 4, 2025 | markets.businessinsider.comBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy ResearchMarch 4, 2025 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for DRUG EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Bright Minds Biosciences in a research note issued to investors on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now forecastFebruary 22, 2025 | marketbeat.comBright Minds Biosciences' (DRUG) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $85.00 price objective on shares of Bright Minds Biosciences in a research report on Wednesday.February 20, 2025 | marketbeat.comBright Minds Biosciences (DRUG) Receives a New Rating from Piper SandlerFebruary 14, 2025 | markets.businessinsider.comBright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPSBright Minds Biosciences (NASDAQ:DRUG - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.24.February 14, 2025 | marketbeat.comBiotechs on the Brink: 2 Stocks With Huge Potential (DRUG)BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.February 14, 2025 | marketbeat.comBright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101January 26, 2025 | seekingalpha.comPiper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 24, 2025 | msn.comBright Minds Biosciences initiated with an Overweight at Piper SandlerJanuary 23, 2025 | markets.businessinsider.comYasmeen Rahimi’s Buy Rating on Bright Minds Biosciences Driven by Promising Potential of BMB-101 for Epilepsy TreatmentJanuary 23, 2025 | markets.businessinsider.comCantor Fitzgerald Forecasts DRUG FY2025 EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will poJanuary 23, 2025 | marketbeat.comPiper Sandler sets $93 target for Bright Minds Biosciences stockJanuary 23, 2025 | msn.com Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address DRUG Media Mentions By Week DRUG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRUG News Sentiment▼1.900.68▲Average Medical News Sentiment DRUG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRUG Articles This Week▼12▲DRUG Articles Average Week Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvation Bio News Today uniQure News Today Xeris Biopharma News Today Immunome News Today Pharming Group News Today ArriVent BioPharma News Today Intellia Therapeutics News Today Cronos Group News Today Replimune Group News Today Immatics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRUG) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
